Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+111.8%
5Y CAGR+65.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+111.8%/yr
vs -18.7%/yr prior
5Y CAGR
+65.2%/yr
Recent acceleration
Acceleration
+130.6pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
12.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 45.31% |
| Q3 2025 | 7.80% |
| Q2 2025 | -19.14% |
| Q1 2025 | 49.79% |
| Q4 2024 | -8.90% |
| Q3 2024 | 11.59% |
| Q2 2024 | -8.07% |
| Q1 2024 | 89.14% |
| Q4 2023 | -50.80% |
| Q3 2023 | 35.69% |
| Q2 2023 | -52.70% |
| Q1 2023 | -34.34% |
| Q4 2022 | 4.77% |
| Q3 2022 | -0.68% |
| Q2 2022 | -4.57% |
| Q1 2022 | 16.31% |
| Q4 2021 | -27.30% |
| Q3 2021 | 8.88% |
| Q2 2021 | -0.11% |
| Q1 2021 | 11.15% |
| Q4 2020 | 3.68% |
| Q3 2020 | 2.72% |
| Q2 2020 | -11.98% |
| Q1 2020 | 13.35% |
| Q4 2019 | -1.49% |
| Q3 2019 | 9.35% |
| Q2 2019 | 20.80% |
| Q1 2019 | -20.47% |
| Q4 2018 | 24.06% |
| Q3 2018 | 2.78% |
| Q2 2018 | -3.96% |
| Q1 2018 | -2.76% |
| Q4 2017 | 6.97% |
| Q3 2017 | -6.21% |
| Q2 2017 | -6.88% |
| Q1 2017 | 6.38% |
| Q4 2016 | -28.06% |
| Q3 2016 | -7.43% |
| Q2 2016 | -3.88% |
| Q1 2016 | 9.72% |